undamentalytics Newsletter
Sign in

20/20 Biolabs, Inc. revenue

20/20 Biolabs, Inc.'s revenue was $2.0m in fiscal 2025, up 16.7% on the year before.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025
Revenue1,7522,045
Growth on the year before—+16.7%
Gross profit360605
Gross margin20.6%29.6%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
One Test $1.8M 88.2% ▲ 21.0%
Bio Check $152,047 7.4% ▼ 14.2%
CLI Ax $89,379 4.4% ▲ 6.2%

From 20/20 Biolabs, Inc.'s 10-K filed March 31, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from 20/20 Biolabs, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to 20/20 Biolabs, Inc.